Medicare Coverage of Novo’s Semaglutide for CVD Could Cost $145B Annually: Study

The number of patients who will be eligible for Novo Nordisk’s blockbuster GLP-1 under new Medicare Part D plan guidelines will vary depending on how cardiovascular disease is defined, according to researchers.